Literature DB >> 16936228

Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma.

Kristin Gustafsson1, Birger Christensson, Birgitta Sander, Jenny Flygare.   

Abstract

We have recently shown that cannabinoids induce growth inhibition and apoptosis in mantle cell lymphoma (MCL), a malignant B-cell lymphoma that expresses high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In the current study, the role of each receptor and the signal transduction triggered by receptor ligation were investigated. Induction of apoptosis after treatment with the synthetic agonists R(+)-methanandamide [R(+)-MA] and Win55,212-2 (Win55; (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo-[1,2,3-d,e]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone) was dependent on both cannabinoid receptors, because pretreatment with N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716A) and N-((1S)-endo-1,3,3-trimethyl bicyclo heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide) (SR144528), specific antagonists to CB(1) and CB(2), respectively, abrogated caspase-3 activity. Preincubation with the inhibitors 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580) and 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB202190) showed that phosphorylation of MAPK p38 was implicated in the signal transduction leading to apoptosis. Treatment with R(+)-MA and Win55 was associated with accumulation of ceramide, and pharmacological inhibition of ceramide synthesis de novo prevented both p38 activation and mitochondria depolarization assessed by binding of 3,3'-dihexyloxacarbocyanine iodide (DiOC(6)). In contrast, the pancaspase inhibitor z-Val-Ala-Asp(Ome)-CH(2)F (z-VAD-FMK) did not protect the mitochondrial integrity. Taken together, these results suggest that concurrent ligation of CB(1) and CB(2) with either R(+)-MA or Win55 induces apoptosis via a sequence of events in MCL cells: accumulation of ceramide, phosphorylation of p38, depolarization of the mitochondrial membrane, and caspase activation. Although induction of apoptosis was observed in both MCL cell lines and primary MCL, normal B cells remained unaffected. The present data suggest that targeting CB(1)/CB(2) may have therapeutic potential for the treatment of mantle cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936228     DOI: 10.1124/mol.106.025981

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

1.  Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.

Authors:  Anju Preet; Zahida Qamri; Mohd W Nasser; Anil Prasad; Konstantin Shilo; Xianghong Zou; Jerome E Groopman; Ramesh K Ganju
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-19

2.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

Review 3.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.

Authors:  Sreemanti Basu; Bonnie N Dittel
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 4.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

5.  Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Authors:  Zahida Qamri; Anju Preet; Mohd W Nasser; Caroline E Bass; Gustavo Leone; Sanford H Barsky; Ramesh K Ganju
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

6.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

7.  Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors:  Jahan P Marcu; Rigel T Christian; Darryl Lau; Anne J Zielinski; Maxx P Horowitz; Jasmine Lee; Arash Pakdel; Juanita Allison; Chandani Limbad; Dan H Moore; Garret L Yount; Pierre-Yves Desprez; Sean D McAllister
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Authors:  Kristin Gustafsson; Birgitta Sander; Jacek Bielawski; Yusuf A Hannun; Jenny Flygare
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

9.  Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway.

Authors:  Yi-Jie Liu; Hong-Bo Fan; Yi Jin; Chun-Guang Ren; Xiao-E Jia; Lei Wang; Yi Chen; Mei Dong; Kang-Yong Zhu; Zhi-Wei Dong; Bai-Xin Ye; Zhong Zhong; Min Deng; Ting Xi Liu; Ruibao Ren
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

10.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.